Rhinology最新文献_第6页

Topical intranasal anesthesia impairs trigeminal function and airflow perception. 局部鼻内麻醉损害三叉神经功能和气流感知。

IF 4.8 2区医学

Rhinology Pub Date : 2025-02-01 DOI: 10.4193/Rhin

C Migneault-Bouchard, F J M Boselie, J Frasnelli

{"title":"Topical intranasal anesthesia impairs trigeminal function and airflow perception.","authors":"C Migneault-Bouchard, F J M Boselie, J Frasnelli","doi":"10.4193/Rhin","DOIUrl":"10.4193/Rhin","url":null,"abstract":"Background: Impairment of airflow perception by the intranasal trigeminal system may explain chronic nasal obstruction (CNO),especially in cases where no major deformity or mucosal inflammation can explain reduced airflow. We aim to characterize the effect of topical intranasal anesthesia on intranasal trigeminal sensitivity and consequently the sensation of nasal obstruction.Methodology: We performed a crossover study of 16 healthy subjects, randomised for either treatment (topical intranasal anesthesia with 10% Xylocaine) or placebo (saline solution). We used the Trigeminal Lateralization Task (TLT) with eucalyptol to assess trigeminal sensitivity. We measured nasal patency objectively with Peak Nasal Inspiratory Flow (PNIF), and subjectively with a Visual Analog Scale (VAS), the Empty Nose Syndrome 6-Item Questionnaire (ENS6Q), and the Nasal Obstruction Symptom Evaluation (NOSE) questionnaire.Results: Topical intranasal anesthesia significantly reduced intranasal trigeminal sensitivity. Further, after topical intranasal anesthesia,reduced trigeminal sensitivity was associated with the subjectively reduced nasal patency, as highlighted by ENS6Q and NOSE scores.Conclusions: Topical intranasal anesthesia reduces intranasal trigeminal function resulting in subjectively reduced nasal patency. In future studies, the relation of reduced intranasal trigeminal function and subjective nasal obstruction needs to be addressed to open an avenue for potential interventions for an important portion of ENT patients.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":"63 1","pages":"85-91"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing the research on management of global airway disease: insights from a post hoc analysis. 推进全球气道疾病管理研究：来自事后分析的见解。

IF 4.8 2区医学

Rhinology Pub Date : 2025-02-01 DOI: 10.4193/Rhin25.901

S Toppila-Salmi

引用次数: 0

Global airway disease: mepolizumab simultaneously improves outcomes in severe CRSwNP and asthma. 全球气道疾病：mepolizumab同时改善严重CRSwNP和哮喘的预后

IF 4.8 2区医学

Rhinology Pub Date : 2025-02-01 DOI: 10.4193/Rhin24.337

J Mullol, V Backer, J Constantinidis, I Eguiluz-Gracia, A L Moure, R Cuervo-Pinto, L Zhang, P Shah, W Kerr, P Hellings

引用次数: 0

Nasal secretions trace epithelial type 2 response to allergen-specific immunotherapy. 鼻分泌物追踪上皮2型对过敏原特异性免疫治疗的反应。

IF 4.8 2区医学

Rhinology Pub Date : 2025-02-01 DOI: 10.4193/Rhin24.038

C A Jakwerth, U M Zissler, M Oelsner, L Pechtold, L Zur Bonsen, M Plaschke, J Kau, M Davidovic, M Mootz, B Haller, A M Chaker, C B Schmidt-Weber

{"title":"Nasal secretions trace epithelial type 2 response to allergen-specific immunotherapy.","authors":"C A Jakwerth, U M Zissler, M Oelsner, L Pechtold, L Zur Bonsen, M Plaschke, J Kau, M Davidovic, M Mootz, B Haller, A M Chaker, C B Schmidt-Weber","doi":"10.4193/Rhin24.038","DOIUrl":"10.4193/Rhin24.038","url":null,"abstract":"Background: Allergen-specific immunotherapy (AIT) is a disease-modifying therapy and is effective to reduce the symptoms of grass pollen-allergy. The airway epithelium of these patients releases inflammatory mediators including type-2 cytokines, which are associated with cellular processes involved in the symptomatic response of the affected tissue. Aim of the study was to identify epithelial biomarkers indicating AIT progress.Methods: In an exploratory, observational allergy cohort, we longitudinally phenotyped 56 grass pollen-allergic patients undergoing AIT for over three years and 18 controls using nasal secretions at critical time windows during therapy to assess peak-season responses along the course of therapy. Type-2 cytokine protein levels were analyzed using the high-sensitivity multiplex electrochemiluminescence mesoscale technique.Results: The type-2 cytokines CCL26 and POSTN oscillated seasonally, in contrast to TSLP and IL-33. However, only POSTN was reduced over the three-year AIT progression. In addition to POSTN, IL-24 and IL-37 levels were continuously reduced during AIT, while IFN-g and CCL27 were increased. Compared to healthy individuals, AIT did not restore healthy secretion levels but rather induced a novel homeostasis CONCLUSION: Nasal secretions trace the epithelial response during different phases of AIT. We demonstrate that AIT only partially controls the epithelial type 2 cytokine CCL26, which also adapts to seasonal changes, while POSTN and IL-24 are potential indicators of therapy success. Therefore, nasal secretions represent a promising, non-invasive tool for monitoring seasonal progress of AIT.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"43-53"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142807920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Omalizumab reduces allergic rhinitis symptoms due to Japanese cedar pollen by improving eosinophilic inflammation. 奥马珠单抗可通过改善嗜酸性粒细胞炎症，减轻日本杉树花粉引起的过敏性鼻炎症状。

IF 4.8 2区医学

Rhinology Pub Date : 2025-02-01 DOI: 10.4193/Rhin24.105

K Hirano, I Suzaki, N Okuzawa, A Oki, Y Otani, M Takeuchi, A Minoura, K Murakami, Y Ihara, H Kato, Y Watanabe, T Shimane

{"title":"Omalizumab reduces allergic rhinitis symptoms due to Japanese cedar pollen by improving eosinophilic inflammation.","authors":"K Hirano, I Suzaki, N Okuzawa, A Oki, Y Otani, M Takeuchi, A Minoura, K Murakami, Y Ihara, H Kato, Y Watanabe, T Shimane","doi":"10.4193/Rhin24.105","DOIUrl":"10.4193/Rhin24.105","url":null,"abstract":"Seasonal allergic rhinitis caused by Japanese cedar pollen (SAR-JCP) is a serious social problem in Japan, affecting 38.8% of the population. Omalizumab, a recombinant humanised monoclonal anti-immunoglobulin (Ig)E antibody, reduces serum-free IgE levels by 84â€\"99%. The reduction of serum-free IgE levels induced by omalizumab ultimately downregulates FcÎ#181;RI expression in basophils and mast cells. Omalizumab significantly reduces nasal symptoms and improves the quality of life in patients with allergic rhinitis ; however, other than a decrease in free IgE, its biomarker activity is unclear. Allergic rhinitis reactions are more pronounced in nasal secretions and mucosa than in serum; however, no studies have examined the changes in proteins in nasal secretions after omalizumab administration. In this study, we aimed to elucidate the pathophysiology of the effect of omalizumab. This may serve as a basis for the identification of new biomarkers through the examination of proinflammatory proteins in nasal secretions, which may reflect the pathophysiology more accurately than peripheral blood.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"116-117"},"PeriodicalIF":4.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142353028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Diversity" in rhinology. 鼻科学中的“多样性”。

IF 4.8 2区医学

Rhinology Pub Date : 2024-12-03 DOI: 10.4193/Rhin24.906

S Reitsma

引用次数: 0

IL-17A disrupts the nasal mucosal epithelial barrier in patients with chronic rhinosinusitis by activating the ERK/STAT3 pathway. IL-17A 通过激活 ERK/STAT3 通路破坏慢性鼻炎患者的鼻粘膜上皮屏障。

IF 4.8 2区医学

Rhinology Pub Date : 2024-12-01 DOI: 10.4193/Rhin24.127

H Wu, Y Li, X Li, W Huang, Z Huang, X Lai, J Ma, Y Jiang, Y Zhang, L Chang, G Zhang

{"title":"IL-17A disrupts the nasal mucosal epithelial barrier in patients with chronic rhinosinusitis by activating the ERK/STAT3 pathway.","authors":"H Wu, Y Li, X Li, W Huang, Z Huang, X Lai, J Ma, Y Jiang, Y Zhang, L Chang, G Zhang","doi":"10.4193/Rhin24.127","DOIUrl":"10.4193/Rhin24.127","url":null,"abstract":"Background: The mucosal epithelial barrier, the first line of immune defense, is vulnerable to allergens, pathogens, and inflammatory cytokines, contributing to CRS development. Our previous studies found high interleukin-17A(IL-17A) expression correlated with CRS severity and low glucocorticoid efficacy. The role of IL-17A in disrupting the nasal mucosal epithelial barrier leading to CRS remains unclear. We aimed to investigate how IL-17A promoting epithelial barrier damage and identify new treatment targets for CRS.Methodology: Nasal tissue samples from 36 CRSwNP, 34 CRSsNP, and 39 controls were examined for the expression of IL-17A and tight junction (TJ) proteins using qRT-PCR, immunohistochemistry and immunofluorescence. The integrity of TJs and signaling pathways activation were observed using western blot, immunofluorescence, TEER and FITCâ€\"FD4, transmission electron microscopy before and after IL-17A stimulation in human primary nasal epithelial cells (hNECs). Concurrently, studies were also conducted in an CRS mouse model induced by anti-IL-17A neutralizing antibody administration.Results: TJs expression in the nasal mucosa of CRS patients was lower than in controls. IL-17A stimulation reduced TJs expression and TEER while increasing hNECs permeability. Inhibition of the (ERK/STAT3) pathway reversed the downregulation of TJs and the disruption of the epithelial barrier induced by IL-17A stimulation. In the CRS mouse model, anti-IL-17A antibody treatment rescued the nasal mucosal epithelial barrier.Conclusions: IL-17A disrupts the nasal mucosal epithelial barrier by activating the ERK/STAT3 pathway in patients with CRS.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"726-738"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA. 甲泼尼单抗对 CRSwNP 睡眠障碍的影响：SYNAPSE 和 MUSCA 的事后分析。

IF 4.8 2区医学

Rhinology Pub Date : 2024-12-01 DOI: 10.4193/Rhin24.021

J Mullol, W J Fokkens, S G Smith, T Keeley, L Zhang, P Howarth, R H Chan, C Bachert

{"title":"The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA.","authors":"J Mullol, W J Fokkens, S G Smith, T Keeley, L Zhang, P Howarth, R H Chan, C Bachert","doi":"10.4193/Rhin24.021","DOIUrl":"10.4193/Rhin24.021","url":null,"abstract":"Background: The impact of mepolizumab on impaired sleep, one of the most bothersome symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), is unknown. This study aimed to determine the effect of mepolizumab and impact of comorbid upper and lower airway disease and blood eosinophil count (BEC) on sleep-/fatigue-related outcomes in CRSwNP.Methods: This was an analysis of the Phase III SYNAPSE and MUSCA (NCT03085797/NCT02281318) trials of mepolizumab in patients with severe CRSwNP and severe asthma, respectively. Endpoints included change from baseline in 22-item Sino-Nasal Outcome Test (SNOT-22) sleep and fatigue domains (SYNAPSE: Weeks 24 and 52; MUSCA: Week 24) in the overall populations and post hoc subgroups (SYNAPSE: comorbid asthma, comorbid non-steroidal anti-inflammatory drug-exacerbated respiratory disease [N-ERD] and BEC; MUSCA: comorbid CRSwNP).Results: In SYNAPSE, 289/407 patients with severe CRSwNP had comorbid asthma, 108 had N-ERD, and 278 had BEC ≥300 cells/µL. In MUSCA, 105/551 patients with severe asthma had comorbid CRSwNP. Baseline sleep and fatigue scores were worse in patients with comorbid airway disease and higher BEC. Improvements from baseline in sleep and fatigue scores were greater with mepolizumab versus placebo at Week 52 in SYNAPSE (difference in least squares mean change: -2.7 [sleep], -3.4 [fatigue], and Week 24 in SYNAPSE (-1.6 and -2.2) and MUSCA (-0.8 and -1.2), with consistent results across comorbidity and BEC subgroups.Conclusion: Mepolizumab improves sleep and fatigue in severe CRSwNP, irrespective of comorbid airway disease and BEC, with consistent effects in severe asthma with and without comorbid CRSwNP.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"669-680"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142353031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in chronic rhinosinusitis: pathophysiology, treatments, and outcome measures. 慢性鼻炎的最新进展：病理生理学、治疗方法和结果测量。

IF 4.8 2区医学

Rhinology Pub Date : 2024-12-01 DOI: 10.4193/Rhin24.801

W J Fokkens, A R Sedaghat, M B Soyka, S Reitsma

引用次数: 0

SNOT-22 in general population, a Spanish cohort study with an updated meta-analysis. SNOT-22 在普通人群中的应用，一项西班牙队列研究及最新荟萃分析。

IF 4.8 2区医学

Rhinology Pub Date : 2024-12-01 DOI: 10.4193/Rhin24.233

L N Pineros-Garcia, N I Gonzalez-Sanchez, C Calvo-Henrique, M J Rojas-Lechuga, C Hopkins, J Mullol, I Alobid

{"title":"SNOT-22 in general population, a Spanish cohort study with an updated meta-analysis.","authors":"L N Pineros-Garcia, N I Gonzalez-Sanchez, C Calvo-Henrique, M J Rojas-Lechuga, C Hopkins, J Mullol, I Alobid","doi":"10.4193/Rhin24.233","DOIUrl":"10.4193/Rhin24.233","url":null,"abstract":"Background: Olfactory loss (OL) has emerged as one of the most prevalent and debilitating symptoms of SARS-CoV-2 infection and long-COVID-19. The present prospective observational study aimed to evaluate the efficacy of olfactory training (OT) on orthonasal and retronasal olfactory function in a cohort of individuals with persistent post-COVID-19 OL.Methodology: Participants with post-COVID-19 olfactory impairment underwent 4 months of OT, self-assessing their smell perception and undergoing comprehensive psychophysical evaluation of orthonasal and retronasal olfaction at baseline and after training. Orthonasal olfactory function was assessed using the extended Sniffin' Sticks test battery. Retronasal olfactory function was tested with powdered aromas.Results: Among 114 participants with post-COVID-19 olfactory loss, adherence to OT was 60%. In adherents, the average increase in composite TDI score was 6.0 points compared to 2.6 points in non-adherents. Fifty-seven percent of adherent participants achieved a clinically significant improvement in TDI score (≥ 5.5 points), compared to 22% of non-adherents. In retronasal olfactory identification, 56% of adherents achieved a clinically significant improvement (≥4 points), compared to 16% of non-adherents.Conclusion: Adherence to a 4-month OT regimen can yield clinically meaningful improvements in both orthonasal and retronasal olfactory function among individuals with persistent post-COVID-19 olfactory dysfunction.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":"700-709"},"PeriodicalIF":4.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142294345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0